New anticoagulants in ischemic heart disease (Q28193160)

Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction

Europe PubMed Central

title

New anticoagulants in ischemic heart disease (English)

0 references

1 reference

1 reference

coronary artery disease

1 reference

F W A Verheugt

1

0 references

language of work or name

English

0 references

publication date

22 October 2005

0 references

published in

Presse médicale

0 references

volume

34

0 references

issue

18

0 references

page(s)

1325-9

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2805%2984181-8

7 January 2021

Acute myocardial infarction: Intracoronary application of nitroglycerin and streptokinase

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2805%2984181-8

7 January 2021

Effect of continued rt-PA administration on the residual stenosis after initially successful recanalization in acute myocardial infarction--a quantitative coronary angiography study of a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2805%2984181-8

7 January 2021

Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2805%2984181-8

7 January 2021

Increased morning incidence of myocardial infarction in the ISAM Study: absence with prior beta-adrenergic blockade. ISAM Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2805%2984181-8

7 January 2021

Effect of propranolol (long-acting) on the circadian fluctuation of tissue-plasminogen activator and plasminogen activator inhibitor-1

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2805%2984181-8

7 January 2021

Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2805%2984181-8

7 January 2021

Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2805%2984181-8

7 January 2021

Reocclusion: the flip side of coronary thrombolysis

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2805%2984181-8

7 January 2021

Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2805%2984181-8

7 January 2021

Management of acute myocardial infarction in patients presenting with ST-segment elevation

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2805%2984181-8

7 January 2021

Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2805%2984181-8

7 January 2021

The low-molecular-weight heparin dalteparin as adjuvant therapy in acute myocardial infarction: the ASSENT PLUS study

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2805%2984181-8

7 January 2021

Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II)

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2805%2984181-8

7 January 2021

Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. The AMI-SK study

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2805%2984181-8

7 January 2021

A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2805%2984181-8

7 January 2021

Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2805%2984181-8

7 January 2021

Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomi

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2805%2984181-8

7 January 2021

Reactivation of ischemic events in acute coronary syndromes: results from GUSTO-IIb. Gobal Use of Strategies To Open occluded arteries in acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2805%2984181-8

7 January 2021

Oral anticoagulation for acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2805%2984181-8

7 January 2021

Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2805%2984181-8

7 January 2021

Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2805%2984181-8

7 January 2021

Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2805%2984181-8

7 January 2021

Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2805%2984181-8

7 January 2021

Warfarin, aspirin, or both after myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2805%2984181-8

7 January 2021

Progression of the culprit lesion in unstable coronary artery disease with warfarin and aspirin versus aspirin alone: preliminary study.

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2805%2984181-8

7 January 2021

Effect of fixed low-dose warfarin added to aspirin in the long term after acute myocardial infarction; the LoWASA Study

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2805%2984181-8

7 January 2021

Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2805%2984181-8

7 January 2021

Can we pull the plug on warfarin in atrial fibrillation?

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2805%2984181-8

7 January 2021